IGF2BP2 and pancreatic adenocarcinoma: In this study, we suggest a possibility of the mechanism for stabilizing PLK1 expression by the METTL3–IGF2BP2 pathway in pancreatic adenocarcinoma, which may be a new therapeutic target.